Capricor Therapeutics (NASDAQ:CAPR) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $40.00 price objective on the biotechnology company’s stock.

A number of other equities analysts also recently commented on CAPR. Oppenheimer assumed coverage on Capricor Therapeutics in a research note on Friday, May 17th. They issued an outperform rating and a $14.00 price target for the company. LADENBURG THALM/SH SH lifted their target price on Capricor Therapeutics from $24.00 to $25.00 and gave the company a buy rating in a research note on Tuesday, May 14th. StockNews.com downgraded Capricor Therapeutics from a hold rating to a sell rating in a research note on Tuesday, May 14th. Finally, Cantor Fitzgerald restated an overweight rating and issued a $8.00 target price on shares of Capricor Therapeutics in a research note on Tuesday, May 14th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $21.75.

Capricor Therapeutics Stock Performance

NASDAQ:CAPR opened at $4.83 on Tuesday. The company has a market capitalization of $154.46 million, a price-to-earnings ratio of -5.55 and a beta of 4.00. Capricor Therapeutics has a one year low of $2.68 and a one year high of $8.22. The stock has a 50-day simple moving average of $5.36 and a 200 day simple moving average of $5.15.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.20). The firm had revenue of $4.91 million during the quarter, compared to analyst estimates of $10.00 million. Capricor Therapeutics had a negative return on equity of 231.68% and a negative net margin of 89.72%. On average, equities research analysts forecast that Capricor Therapeutics will post -1.04 EPS for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after buying an additional 200,499 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of Capricor Therapeutics during the first quarter worth approximately $40,000. Jump Financial LLC acquired a new position in shares of Capricor Therapeutics during the fourth quarter worth approximately $258,000. Finally, Citigroup Inc. acquired a new position in shares of Capricor Therapeutics during the third quarter worth approximately $211,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.